Literature DB >> 23494857

Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Sinthiya Punnialingam1, Munther A Khamashta.   

Abstract

Antiphospholipid syndrome (APS) is an auto-immune thrombophilia for which anti-thrombotic medication is necessary for long-term management to reduce thrombotic risk or pregnancy morbidity. Choosing the type of pharmacological treatment, i.e. the intensity and duration of anticoagulation, depends on the severity of an individual's APS and the risk of bleeding. This article reviews the current literature on anticoagulation therapy, provides recommendations on when to initiate therapy, and suggests possible alternatives for optimisation of management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494857     DOI: 10.1007/s11926-013-0318-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  52 in total

Review 1.  Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.

Authors:  Angel Lanas; James Scheiman
Journal:  Curr Med Res Opin       Date:  2007-01       Impact factor: 2.580

2.  Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.

Authors:  M Yasuda; K Takakuwa; A Tokunaga; K Tanaka
Journal:  Obstet Gynecol       Date:  1995-10       Impact factor: 7.661

3.  The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.

Authors:  C J Lockwood; R Romero; R F Feinberg; L P Clyne; B Coster; J C Hobbins
Journal:  Am J Obstet Gynecol       Date:  1989-08       Impact factor: 8.661

4.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

5.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

Authors:  Rikke Sørensen; Morten L Hansen; Steen Z Abildstrom; Anders Hvelplund; Charlotte Andersson; Casper Jørgensen; Jan K Madsen; Peter R Hansen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

Review 6.  The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

Authors:  D J Wallace; M Linker-Israeli; A L Metzger; V J Stecher
Journal:  Lupus       Date:  1993-02       Impact factor: 2.911

7.  Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition).

Authors:  Terese T Horlocker; Denise J Wedel; John C Rowlingson; F Kayser Enneking; Sandra L Kopp; Honorio T Benzon; David L Brown; John A Heit; Michael F Mulroy; Richard W Rosenquist; Michael Tryba; Chun-Su Yuan
Journal:  Reg Anesth Pain Med       Date:  2010 Jan-Feb       Impact factor: 6.288

8.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry.

Authors:  G Finazzi; V Brancaccio; M Moia; N Ciaverella; M G Mazzucconi; P C Schinco; M Ruggeri; E M Pogliani; G Gamba; E Rossi; F Baudo; C Manotti; A D'Angelo; G Palareti; V De Stefano; M Berrettini; T Barbui
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

9.  Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals.

Authors:  José A Girón-González; Enrique García del Río; Carmen Rodríguez; Javier Rodríguez-Martorell; Ascensión Serrano
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

10.  Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort.

Authors:  B E Tan; B Y H Thong; S Shivananda; W W Han; H H Chng
Journal:  Lupus       Date:  2009-07       Impact factor: 2.911

View more
  5 in total

Review 1.  Management of recurrent thrombosis in antiphospholipid syndrome.

Authors:  Cecilia Nalli; Laura Andreoli; Cinzia Casu; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

Review 2.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

Review 3.  Treatment of the antiphospholipid syndrome.

Authors:  Monica Galli
Journal:  Auto Immun Highlights       Date:  2013-12-22

4.  [Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome].

Authors:  Z Y Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

5.  Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events.

Authors:  José A Martínez-Flores; Manuel Serrano; Dolores Pérez; Gómez de la Cámara A; David Lora; Luis Morillas; Rosa Ayala; Estela Paz-Artal; José M Morales; Antonio Serrano
Journal:  J Atheroscler Thromb       Date:  2016-04-11       Impact factor: 4.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.